Abstract：
OBJECTIVE: The use of herbal medicine is widespread among oncology patients, with potentially negative interactions with anticancer drugs. This study identified herbal products being used among a cohort of oncology patients, assessing the risk for an herb-drug interaction.
METHODS: Herbal medicine use was examined among 42 oncology patients, identifying potential herb-drug interactions using four online sites. The risk for an interaction was scored using the Working Group on Pharmacotherapy and Drug Information of the Royal Dutch Association for the Advancement of Pharmacy (KNMP).
RESULTS: Most patients (62%) reported herbal medicine use, with 70 products identified; 8 herbs and 13 herbal formulas with unidentified components; and 24 anticancer drugs. Herbal medicine use was more prevalent among female patients (p=0.038), with only nine potential herb-drug interactions identified on at least one site. A maximal KNMP Score of 1 (ie, incomplete published case report) was found with only one interaction.
CONCLUSIONS: The risk for interactions between herbal products and anticancer drugs is difficult to predict, with online search engines providing limited and inconsistent information. Clinical implications of herb-antitumor drug interactions need to be better understood, enabling patients and their oncology healthcare providers to make informed decisions regarding their care.
METHODS: Herbal medicine use was examined among 42 oncology patients, identifying potential herb-drug interactions using four online sites. The risk for an interaction was scored using the Working Group on Pharmacotherapy and Drug Information of the Royal Dutch Association for the Advancement of Pharmacy (KNMP).
RESULTS: Most patients (62%) reported herbal medicine use, with 70 products identified; 8 herbs and 13 herbal formulas with unidentified components; and 24 anticancer drugs. Herbal medicine use was more prevalent among female patients (p=0.038), with only nine potential herb-drug interactions identified on at least one site. A maximal KNMP Score of 1 (ie, incomplete published case report) was found with only one interaction.
CONCLUSIONS: The risk for interactions between herbal products and anticancer drugs is difficult to predict, with online search engines providing limited and inconsistent information. Clinical implications of herb-antitumor drug interactions need to be better understood, enabling patients and their oncology healthcare providers to make informed decisions regarding their care.
摘要：
目的：中药的使用在肿瘤患者中很普遍，与抗癌药物有潜在的负面相互作用。这项研究确定了一组肿瘤患者中使用的草药产品，评估草药-药物相互作用的风险。
方法：在42名肿瘤患者中检查了草药使用情况，使用四个在线网站识别潜在的草药-药物相互作用。使用荷兰皇家药学促进协会（KNMP）的药物治疗和药物信息工作组对相互作用的风险进行评分。
结果：大多数患者（62%）报告使用草药，已确定70种产品；8种草药和13种成分不明的草药配方；和24种抗癌药物。草药使用在女性患者中更为普遍(p=0.038)，在至少一个部位仅发现了9种潜在的草药-药物相互作用。最大KNMP得分为1（即，不完整的已发布病例报告）仅发现一种相互作用。
结论：草药产品和抗癌药物之间相互作用的风险很难预测，在线搜索引擎提供有限且不一致的信息。需要更好地理解草药-抗肿瘤药物相互作用的临床意义，使患者和他们的肿瘤学保健提供者能够就他们的护理做出明智的决定。
方法：在42名肿瘤患者中检查了草药使用情况，使用四个在线网站识别潜在的草药-药物相互作用。使用荷兰皇家药学促进协会（KNMP）的药物治疗和药物信息工作组对相互作用的风险进行评分。
结果：大多数患者（62%）报告使用草药，已确定70种产品；8种草药和13种成分不明的草药配方；和24种抗癌药物。草药使用在女性患者中更为普遍(p=0.038)，在至少一个部位仅发现了9种潜在的草药-药物相互作用。最大KNMP得分为1（即，不完整的已发布病例报告）仅发现一种相互作用。
结论：草药产品和抗癌药物之间相互作用的风险很难预测，在线搜索引擎提供有限且不一致的信息。需要更好地理解草药-抗肿瘤药物相互作用的临床意义，使患者和他们的肿瘤学保健提供者能够就他们的护理做出明智的决定。
